Sensei Biotherapeutics Q3 loss narrows; reduces workforce by 65%

Faeth Therapeutics,

14/11/2025 12:38

Overview

Sensei Biotherapeutics reports Q3 net loss of $4.6 mln, down from $7.3 mln last year

Company reduces workforce by 65% to preserve cash

Outlook

Sensei Biotherapeutics exploring strategic alternatives, including asset sales and potential merger

Company implements workforce reduction to preserve cash amid strategic review

Sensei retains small team for compliance and strategic exploration

Result Drivers

WORKFORCE REDUCTION - Sensei reduced its workforce by approximately 65% to preserve cash amid strategic review

R&D expenses were $2.5 million for the quarter ended September 30, 2025, compared to $4.6 million for the quarter ended September 30, 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$3.62
Q3 Net Income
-$4.57 mln
Q3 Income From Operations
-$4.85 mln
Q3 Operating Expenses
$4.85 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Press Release: ID:nGNX9Xw7bX

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)